IP Library Granted Patent US 7,229,827
Granted Patent B2
US 7,229,827 · App. 10/475,056 · Granted Jun 12, 2007

Method for differentiating mesenchymal stem cells into neural cells

Assignees: FCB-Pharmicell Co., Ltd.; LifeCord International Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,229,827
App. No.
10/475,056
Granted
Jun 12, 2007
Kind
B2
Abstract

A method for differentiating mesenchymal stem cells of bone marrow into neural cells comprises culturing the mesenchymal stem cells in a medium containing epidermal growth factor(EGF), basic fibroblast growth factor(bFGF) and hepatocyte growth factor(HGF), and the neural cells produced thereby can be employed for the treatment of a neural disease.

Claims (7)

1. A method for differentiating mesenchymal stem cells into neural cells, which comprises culturing the mesenchymal stem cells in a medium containing epidermal growth factor (EGF), basic fibroblast growth factor (bFGF) and hepatocyte growth factor (HGF).

2. The method of claim 1 , wherein the mesenchymal stem cells are cultured in a medium containing 1 to 1000 ng/ml of EGF, 1 to 1000 ng/ml of bFGF and 1 to 1000 ng/ml of HGF for more than one week.

3. The method of claim 2 , wherein the culturing is carried out for more than 4 weeks.

4. The method of claim 1 , wherein the mesenchymal stem cells are cultured in a medium containing EGF, bFGF and HGF for more than one week and the resulting differentiated neural cells are allowed to proliferate in a medium containing EGF and bFGF.

5. The method of claim 1 , wherein the mesenchymal stem cells are isolated from human bone marrow.

6. The method of claim 1 , wherein mononuclear cells isolated from bone marrow and containing mesenchymal stem cells are used as a source of mesenchymal stem cells.

7. The method of claim 1 , wherein the neural cells contain neurons and astrocytes.

Assignments (5)
MERGER Recorded Nov 8, 2011
From: FCB-PHARMICELL CO., LTD.
To: PHARMICELL CO., LTD.
Reel/Frame 027192/0053 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2008
From: LIFECORD INTERNATIONAL CO., LTD.
To: LIFECORD INC.
Reel/Frame 020507/0297 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2007
From: KIM, HYUN-SOO
To: FCB-PHARMICELL CO., LTD.
Reel/Frame 019237/0197 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2007
From: LIFECORD, INC.
To: LIFECORD INTERNATIONAL CO., LTD.
Reel/Frame 019237/0226 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2003
From: KIM, HYUN-SOO; YOON, HEE-HOON
To: LIFECORD, INC.; KIM, HYUN-SOO
Reel/Frame 015237/0545 →
Priority Claims (1)
KR 2001-21064 · Apr 19, 2001 · national
Continuity (1)
Related Publication 20040151701A1 · Aug 5, 2004